Jason Gerberry

Although management has largely delivered on the post-spin objectives, Organon & Co. (NYSE: OGN) has no pipeline assets and its financial leverage limits potential M&A to invest in future growth drivers, according to Bank of America (BofA) Securities. The Analyst: Jason Gerberry downgraded...

Xenon Pharmaceuticals Inc’s (NASDAQ: XENE) epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities. The Xenon Pharmaceuticals Analyst: Jason Gerberry initiated coverage of Xenon Pharmaceuticals with a Buy...

Following Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) opioid settlement, the Tel Aviv-Yafo, Israel-based company seems to be making “material progress” in clearing its litigation overhangs. It also has a strong product cycle lined up for 2023 and 2024, according to Bank of...

Axsome Therapeutics Inc (NASDAQ: AXSM) shares rallied 40% on Monday morning after the company received some positive news from the U.S. Food and Drug Administration regarding its AXS-05 novel treatment for MDD (depression). What Happened? Axsome filed an 8K on Monday morning reporting the FDA has...

Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) stock, according to BofA Securities. The Teva Pharmaceutical Industries Analyst: Jason Gerberry upgraded the rating for Teva...

Arcellx (NASDAQ: ACLX) is advancing  into pivotal testing (by year-end 2022) of its B-cell maturation antigen (BCMA) directed combination antiretroviral therapy (CART), known as ddBCMA, for relapsed refractory multiple myeloma, according to BofA Securities. The Arcellx Analyst: Jason Gerberry...

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that could unlock value, according to BofA Securities. The Ionis Pharmaceuticals Analyst:...

Following the recent rally, Alkermes Plc’s (NASDAQ: ALKS) shares have exceeded their fair value and the stock looks “expensive on a relative basis,” according to BofA Securities. The Alkermes Analyst: Jason Gerberry downgraded the rating for Alkermes from Neutral to Underperform,...

Organon & Co (NYSE: OGN), which has recently spun-off from Merck & Co., Inc. (NYSE: MRK), has “inherited a global business across three segments,” namely Women’s Health, Legacy and Biosimilars brands, according to BofA Securities. The Organon Analyst: Jason Gerberry...

FibroGen, Inc. (NASDAQ: FGEN) shares were slumping over 40% following a negative AdCom verdict and a string of downgrades in reaction to the adverse regulatory development. The FibroGen Analyst: BofA Securities analyst Jason Gerberry downgraded FibroGen shares from Buy to Neutral and reduced the...

Over the weekend, Johnson & Johnson (NYSE: JNJ) reached a major opioid litigation settlement that could have broader implications for the biopharmaceutical industry. What Happened? Johnson & Johnson agreed to a $260-million settlement with the state of New York. However, there are still a...

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ: BIIB) stock earlier this month when its Alzheimer's treatment Aduhelm was approved. Details on key catalytic events...

There are challenges to value creation in the proposed separation of Bausch Health Companies Inc’s (NYSE: BHC) Bausch and Lomb (B&L) unit and RemainCo, which will be pharma-focused, according to BofA Securities. The Bausch Health Analyst: Jason Gerberry downgraded the rating for Bausch...

On Tuesday, the Wall Street Journal reported the U.S. Justice Department has indicted Teva Pharmaceutical Industries Ltd (NYSE: TEVA), alleging the company participated in three different drug price-fixing conspiracies. On Wednesday, one Wall Street analyst said the price-fixing charges...

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) provided encouraging updates on its commercial efforts in a recent conference call on the lung cancer drug Zepzelca, according to BofA Securities. The Jazz Pharma Analyst Jason Gerberry maintained a Buy rating on Jazz Pharmaceuticals and raised the price...